{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:06:35Z","timestamp":1784318795940,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40256-025-00734-z","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T05:55:34Z","timestamp":1751090134000},"page":"703-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Disproportionality Analysis of Ivabradine in the US FDA Adverse Event Reporting System: A Real-World Study Across Overall and Indication-Specific Populations"],"prefix":"10.1007","volume":"25","author":[{"given":"Jinghua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"5","key":"734_CR1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10557-020-07124-4","volume":"35","author":"C Chen","year":"2021","unstructured":"Chen C, Kaur G, Mehta PK, et al. Ivabradine in cardiovascular disease management revisited: a review. Cardiovasc Drugs Ther. 2021;35(5):1045\u201356.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"734_CR2","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137\u201361.","journal-title":"Circulation"},{"issue":"14","key":"734_CR3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","volume":"70","author":"JS Koruth","year":"2017","unstructured":"Koruth JS, Lala A, Pinney S, et al. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70(14):1777\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"734_CR4","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.hrthm.2015.09.019","volume":"13","author":"RL Page","year":"2016","unstructured":"Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2016;13(4):e136-221.","journal-title":"Heart Rhythm"},{"issue":"2","key":"734_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.hrthm.2017.10.004","volume":"15","author":"ST Mathew","year":"2018","unstructured":"Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2018;15(2):240\u20137.","journal-title":"Heart Rhythm"},{"issue":"7","key":"734_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacc.2020.12.029","volume":"77","author":"PR Taub","year":"2021","unstructured":"Taub PR, Zadourian A, Lo HC, et al. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2021;77(7):861\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"734_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"key":"734_CR8","first-page":"37","volume":"2014","author":"M Jiang","year":"2014","unstructured":"Jiang M, Wu Y, Shah A, et al. Extracting and standardizing medication information in clinical text - the MedEx-UIMA system. AMIA Jt Summits Transl Sci Proc. 2014;2014:37\u201342.","journal-title":"AMIA Jt Summits Transl Sci Proc."},{"issue":"3","key":"734_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","volume":"26","author":"EG Brown","year":"2003","unstructured":"Brown EG. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 2003;26(3):145\u201358.","journal-title":"Drug Saf"},{"issue":"Suppl 4","key":"734_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12911-023-02375-1","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang X, Feng Y, Li F, et al. Evaluating MedDRA-to-ICD terminology mappings. BMC Med Inform Decis Mak. 2024;23(Suppl 4):299.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"8","key":"734_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"734_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"734_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"30","key":"734_CR14","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","volume":"39","author":"S-J Heo","year":"2020","unstructured":"Heo S-J, Jung I. Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance. Stat Med. 2020;39(30):4636\u201350.","journal-title":"Stat Med"},{"issue":"6","key":"734_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399.","journal-title":"Drug Saf"},{"issue":"6","key":"734_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47(6):575\u201384.","journal-title":"Drug Saf"},{"issue":"9","key":"734_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti M, Antonazzo IC, Diemberger I, et al. Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol. 2021;28(9):983\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"734_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.numecd.2016.02.006","volume":"26","author":"E Raschi","year":"2016","unstructured":"Raschi E, Poluzzi E, Koci A, et al. Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutr Metab Cardiovasc Dis. 2016;26(5):380\u20136.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"25","key":"734_CR19","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.jacc.2020.11.021","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Fuster V. The global burden of cardiovascular diseases and risks: a compass for global action. J Am Coll Cardiol. 2020;76(25):2980\u20131.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"734_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14740338.2019.1612873","volume":"18","author":"EA Bocchi","year":"2019","unstructured":"Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019;18(5):393\u2013402.","journal-title":"Expert Opin Drug Saf"},{"key":"734_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou L, Shen Y, et al. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord. 2024;346:223\u20139.","journal-title":"J Affect Disord"},{"key":"734_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2387316","author":"L Jin","year":"2024","unstructured":"Jin L, Yang K, Wu X, et al. Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects. Expert Opin Drug Saf. 2024. https:\/\/doi.org\/10.1080\/14740338.2024.2387316.","journal-title":"Expert Opin Drug Saf"},{"key":"734_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122636","volume":"346","author":"MR Guedes","year":"2024","unstructured":"Guedes MR, de Noronha SISR, Ch\u00edrico MTT, et al. Ivabradine restores tonic cardiovascular autonomic control and reduces tachycardia, hypertension and left ventricular inflammation in post-weaning protein malnourished rats. Life Sci. 2024;346: 122636.","journal-title":"Life Sci"},{"key":"734_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120919","volume":"308","author":"FAR Gomes","year":"2022","unstructured":"Gomes FAR, Noronha SISR, Silva SCA, et al. Ivabradine treatment lowers blood pressure and promotes cardiac and renal protection in spontaneously hypertensive rats. Life Sci. 2022;308: 120919.","journal-title":"Life Sci"},{"issue":"5","key":"734_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"J Brugada","year":"2020","unstructured":"Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655\u2013720.","journal-title":"Eur Heart J"},{"issue":"2","key":"734_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clinthera.2015.12.018","volume":"38","author":"C Cammarano","year":"2016","unstructured":"Cammarano C, Silva M, Comee M, et al. Meta-analysis of ivabradine in patients with stable coronary artery disease with and without left ventricular dysfunction. Clin Ther. 2016;38(2):387\u201395.","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"734_CR27","first-page":"zuad036.085","volume":"12","author":"S Paula","year":"2023","unstructured":"Paula S, Figueiredo M, Santos M, et al. Predictors of late ventricular tachycardia in acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2023;12(Suppl 1):zuad036.085.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"734_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ahj.2019.12.024","volume":"223","author":"RJ Mentz","year":"2020","unstructured":"Mentz RJ, DeVore AD, Tasissa G, et al. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: results of the PRIME-HF Trial. Am Heart J. 2020;223:98\u2013105.","journal-title":"Am Heart J"},{"key":"734_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijcard.2017.03.131","volume":"240","author":"C Zugck","year":"2017","unstructured":"Zugck C, St\u00f6rk S, St\u00f6ckl G, et al. Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: effect on symptoms, quality of life and hospitalizations. Int J Cardiol. 2017;240:258\u201364.","journal-title":"Int J Cardiol"},{"issue":"4","key":"734_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/FJC.0000000000001209","volume":"79","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wang W, Li H, et al. Ivabradine and atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(4):549\u201357.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"734_CR31","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.hrthm.2023.02.012","volume":"20","author":"A Fontenla","year":"2023","unstructured":"Fontenla A, Tamargo J, Salgado R, et al. Ivabradine for controlling heart rate in permanent atrial fibrillation: a translational clinical trial. Heart Rhythm. 2023;20(6):822\u201330.","journal-title":"Heart Rhythm"},{"issue":"Suppl 1","key":"734_CR32","doi-asserted-by":"publisher","first-page":"hcae070.133","DOI":"10.1093\/qjmed\/hcae070.133","volume":"117","author":"MMA Ibrahim","year":"2024","unstructured":"Ibrahim MMA, Sallam WM, Khorshid HM, et al. Risk of atrial fibrillation induced by ivabradine in correlation with left atrial size. QJM. 2024;117(Suppl 1):hcae070.133.","journal-title":"QJM"},{"key":"734_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2024.109847","volume":"241","author":"N Umeya","year":"2024","unstructured":"Umeya N, Yoshizawa Y, Fukuda K, et al. Detection of retinal dysfunction induced by HCN channel inhibitors using multistep light stimulus and long-duration light stimulus ERG in rats. Exp Eye Res. 2024;241: 109847.","journal-title":"Exp Eye Res"},{"issue":"5","key":"734_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11606-018-4366-1","volume":"33","author":"MR Sterling","year":"2018","unstructured":"Sterling MR, Jannat-Khah D, Vitale S, et al. Can your patients with heart failure see? The prevalence of visual impairment among adults with heart failure. J Gen Intern Med. 2018;33(5):605\u20137.","journal-title":"J Gen Intern Med"},{"key":"734_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071752","volume":"379","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar MM, Shi X, Ramachandran R, et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008\u201319: cross sectional study. BMJ. 2022;379: e071752.","journal-title":"BMJ"},{"issue":"11","key":"734_CR36","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/CIRCULATIONAHA.123.065300","volume":"148","author":"D Perera","year":"2023","unstructured":"Perera D, Morgan HP, Ryan M, et al. Arrhythmia and death following percutaneous revascularization in ischemic left ventricular dysfunction: prespecified analyses from the REVIVED-BCIS2 Trial. Circulation. 2023;148(11):862\u201371.","journal-title":"Circulation"},{"key":"734_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.806366","volume":"13","author":"MJ Cumberland","year":"2022","unstructured":"Cumberland MJ, Riebel LL, Roy A, et al. Basic research approaches to evaluate cardiac arrhythmia in heart failure and beyond. Front Physiol. 2022;13: 806366.","journal-title":"Front Physiol"},{"key":"734_CR38","unstructured":"European Medicines Agency. Inclusion\/exclusion criteria for the \u201cImportant Medical Events\u201d list. EMA\/126913\/2021 Rev. Last updated 26 September 2024. London: EMA; 2023. https:\/\/www.ema.europa.eu\/en\/documents\/other\/inclusion-exclusion-criteria-important-medical-events-ime-list_en.pdf. Accessed 22 Mar 2025."},{"key":"734_CR39","unstructured":"European Medicines Agency. Designated medical event (DME) list. Last updated 15 June 2020. London: EMA; 2020. https:\/\/www.ema.europa.eu\/en\/documents\/other\/designated-medical-event-dme-list_en.xlsx. Accessed 22 Mar 2025."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00734-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00734-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00734-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T23:12:06Z","timestamp":1757200326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00734-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00734-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"22 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jinghua Yang, Cong Zhao, Lan Yang, Yonggang Yang, Nina Wang, Ang Gao, and Xian Wang have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Publicly available datasets were analyzed in this study. These data can be found here:\u00a0.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: Jinghua Yang, Cong Zhao, Lan Yang. and Xian Wang. Methodology: Cong Zhao, Yonggang Yang, and Nina Wang. Formal analysis and investigation: Jinghua Yang, Lan Yang, and Ang Gao. Writing \u2013 original draft preparation: Jinghua Yang, Cong Zhao, Lan Yang, and Xian Wang. Writing \u2013 review and editing: Yonggang Yang Nina Wang, Ang Gao, and Xian Wang. Funding acquisition: Xian Wang. Resources: Jinghua Yang and Xian Wang. Supervision: Ang Gao and Xian Wang.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}